England's respiratory syncytial virus season opened Monday with paediatric leaders warning that nirsevimab catch-up for very preterm infants remains patchy, leaving some high-risk babies unprotected weeks after discharge guidelines said doses should be complete.
Bridget O'Neill reports that three tertiary trusts in the Midlands and North still schedule outpatient nirsevimab clinics into mid-November, beyond the mid-October target for infants discharged outside the traditional RSV window. The monoclonal antibody, offered alongside maternal vaccination, is meant to cut severe lower-respiratory infections in babies born before 32 weeks who may not benefit from maternal shots alone.
Programme design versus ward reality
NHS England expanded selective infant immunisation this season after Joint Committee on Vaccination and Immunisation advice prioritised nirsevimab when available. A single intramuscular dose should be given before or during the first RSV season, ideally before wards fill with winter viruses. Storm Boelo disrupted transport for community nurses in Scotland, but English trusts cite staffing gaps and competing flu campaigns as bigger bottlenecks.
UKHSA surveillance shows RSV positivity still low nationally, which buys time—but neonatologists note lagged curves can jump within two weeks once schools return from half term.
Equity concerns
London and South West maternal vaccine uptake exceeded 70 percent in October reporting, but Midlands integrated care boards trail by double digits. Babies born to unvaccinated mothers in those regions depend entirely on timely nirsevimab. Paediatricians fear a twin-track winter if affluent postcodes finish catch-up first.
Parents should ask discharge planners for a dated appointment, not a leaflet. GP practices can administer doses if hospital clinics overflow, but only if records show eligibility.
What NHS England says
A spokesperson said additional vaccine vials were shipped last week and that trusts must prioritise neonatal units over elective orthopaedic lists when allocating clinic space. O'Neill will track hospitalisation rates by gestational age through December; if gaps persist, expect ministers to face questions about whether storm recovery distracted from a predictable seasonal risk.
Pharmacy leaders said community chemists can stock nirsevimab where hospital cold chains overflow, but only if NHS England funds storage upgrades. Several chains applied for grants last month and await answers.
Neonatal nurses' unions asked for protected training time on intramuscular dosing for tiny infants, noting that skill faded when palivizumab use dropped in some units.
Healthwatch England said parents of preterm infants should receive written immunisation schedules at discharge, mirroring the maternity continuity-of-care packets introduced after neonatal mortality reviews.
